Bonus Episode: Versatope and the Universal Influenza Vaccine with Christopher Locher, PhD

Versatope Therapeutics, Inc. was recently awarded up to $17.9 million by the NIH to develop a universal influenza vaccine. CEO and Co-Founder, Dr. Christopher Locher walks us through the early days of Versatope, and how it has come to be a key player in the fight for influenza prevention. He shares the story of a start-up from inception to the front lines of vaccine development.